Pharmaceuticals
Quantumzyme Validates Sustainable Ibuprofen Manufacturing Process in Peer-Reviewed Publication
Quantumzyme Corp. has published research validating its enzymatic process for sustainable ibuprofen production, representing a significant advancement toward greener pharmaceutical manufacturing with reduced environmental impact.
Pacylex and Heidelberg Pharma Present Promising Zelenirstat ADC Data at World ADC Conference
Pacylex Pharmaceuticals and Heidelberg Pharma are presenting data showing zelenirstat's potential as a novel antibody drug conjugate payload, demonstrating significantly increased potency against breast and prostate cancer cells compared to oral administration alone.
Heidelberg Pharma Reports Promising Clinical Data for Multiple Myeloma Treatment HDP-101
Heidelberg Pharma will present new clinical data showing objective responses and anti-tumor activity in multiple myeloma patients treated with its lead antibody-drug conjugate candidate HDP-101, highlighting its potential to address significant unmet medical needs in relapsed or refractory cases.
Thomas Meier Appointed as New CEO of Medios AG, Signaling Strategic Growth Phase
Medios AG appoints Thomas Meier as new CEO to drive expansion in the European Specialty Pharma market, bringing international leadership experience from Swiss CDMO Bachem Holding AG.
NanoViricides to Present Broad-Spectrum Antiviral Pipeline at Spartan Capital Investor Conference
NanoViricides will present its clinical-stage antiviral drug pipeline at the Spartan Capital Investor Conference, highlighting the potential significance of its platform technology for treating multiple viral diseases including RSV, COVID-19, influenza, and other respiratory infections.
ABVC BioPharma Reports 230% Licensing Revenue Growth and Major Asset Expansion in Q3 2025
ABVC BioPharma achieved significant financial growth with 230% year-over-year licensing revenue increase and 181% asset expansion, driven by strategic investments in Taiwan manufacturing facilities that strengthen the company's global dual-core operational structure.
Quantum BioPharma Announces Private Placement to Strengthen Voting Control and Fund Operations
Quantum BioPharma Ltd. is conducting a $750 private placement that will significantly increase voting control for its key executives while providing working capital for its neurodegenerative and metabolic disorder treatments.
BIO CEO Warns U.S. Could Lose Biotech Leadership to China Within Two Years
GeoVax Labs calls for urgent policy action following Biotechnology Innovation Organization CEO John Crowley's warning that China could overtake U.S. biotech leadership within two years, highlighting the need for vaccine platform diversity, onshoring manufacturing, and protecting immunocompromised populations.
Voyageur Pharmaceuticals Expands into Mexican Healthcare Market Through Phalanx Distribution Partnership
Voyageur Pharmaceuticals has signed a non-exclusive distribution agreement with Mexican company Phalanx to expand access to its barium-based contrast media products in Latin America, representing a strategic move to address growing demand for cost-effective medical imaging solutions in underserved markets.
NanoViricides Reports Promising Anti-Measles Results for Broad-Spectrum Antiviral Candidate NV-387
NanoViricides' experimental drug NV-387 demonstrates strong efficacy against Measles in preclinical studies, potentially addressing the critical gap in approved treatments for the resurgent viral disease.
Soligenix ThermoVax Technology Addresses Critical Vaccine Stability Challenge in Epidemic Response
Soligenix's development of thermostable vaccines that remain stable at high temperatures could significantly reduce global vaccine wastage and improve deployment in outbreak regions where cold chain infrastructure is limited.
Nutriband Advances Abuse-Deterrent Fentanyl Patch Toward FDA Submission Following Regulatory Feedback
Nutriband Inc. has received critical FDA guidance confirming the regulatory pathway for its AVERSA™ Fentanyl abuse-deterrent transdermal system, marking a significant step forward in addressing the opioid crisis through innovative pharmaceutical technology.
Nutriband Founder Returns as CEO to Lead Final Development of Abuse-Deterrent Fentanyl Patch
Nutriband founder Gareth Sheridan has resumed his role as CEO to lead the final development phase of AVERSA Fentanyl, an abuse-deterrent opioid patch with potential peak annual U.S. sales estimated between $80 million and $200 million.
NanoViricides to Present Antiviral Pipeline Updates at PODD 2025 Conference
NanoViricides will showcase its broad-spectrum antiviral drug platform at the upcoming PODD 2025 conference, highlighting progress toward Phase II trials for its lead candidate NV-387 targeting multiple respiratory viruses and MPox.
Annovis Bio Secures $3.4 Million in Registered Direct Offering to Advance Neurodegenerative Disease Therapies
Annovis Bio has raised $3.4 million through a registered direct offering to fund development of treatments for Alzheimer's and Parkinson's diseases, providing crucial capital for advancing late-stage clinical programs targeting neurodegeneration.
Soligenix's HyBryte Shows Promise as Potential First-Line Treatment for Cutaneous T-Cell Lymphoma
Soligenix Inc. is advancing HyBryte as a potential first-line therapy for early-stage cutaneous T-cell lymphoma following promising results from clinical trials that could reshape treatment standards in the rare disease space.
Datavault AI and Wellgistics Health Partner on Blockchain Drug Tracking System
Datavault AI and Wellgistics Health are collaborating to integrate blockchain technology into prescription drug tracking, aiming to improve transparency, efficiency, and patient safety in pharmaceutical distribution.
Nutriband's AVERSA Fentanyl Patch Advances Toward 2026 FDA Submission with $200M Market Potential
Nutriband Inc. is progressing with its abuse-deterrent fentanyl patch technology that could generate up to $800 million in annual sales while addressing the opioid crisis through tamper-resistant transdermal delivery.
Pentixapharm Restructures Operations with 50% Workforce Reduction to Focus on Advanced Clinical Programs
Pentixapharm Holding AG is implementing significant organizational changes including a 50% workforce reduction and reduced early-stage research to concentrate resources on its most advanced clinical development programs, particularly the Phase 3-ready CXCR4 program for treatment-resistant hypertension diagnosis.
Oncotelic Therapeutics Announces Three Abstracts on Deciparticle Everolimus Accepted for 2025 San Antonio Breast Cancer Symposium
Oncotelic Therapeutics will present three abstracts on its investigational intravenous Deciparticle everolimus at the 2025 San Antonio Breast Cancer Symposium, highlighting potential improvements over existing mTOR inhibitors for metastatic breast cancer treatment.
NanoViricides Reports NV-387 Shows Strong Antiviral Activity Against Measles in Preclinical Studies
NanoViricides' clinical lead drug candidate NV-387 demonstrated potent antiviral effects against Measles virus with significant lung protection and extended survival in animal models, potentially offering the first approved treatment for a disease that currently has no specific antiviral therapy.
Datavault AI and Wellgistics Health Partner to Integrate Blockchain Technology for Prescription Drug Tracking
Datavault AI and Wellgistics Health are collaborating to integrate blockchain-enabled PharmacyChain smart contract technology into pharmaceutical distribution, aiming to enhance prescription tracking efficiency, transparency, and patient safety while exploring a revenue-sharing model.
Branded Legacy Advances FDA Pathway for Low-Cost Intranasal Naloxone Alternative
Branded Legacy's subsidiary BioLegacy Evaluative Group is preparing FDA submission materials for a proprietary intranasal naloxone spray that aims to replicate Narcan's performance while reducing costs and improving global accessibility to opioid overdose reversal medication.
Patented Laonson Pill Cutter Launches Globally on Kickstarter with Automatic Center-Aligning Technology
The Laonson Pill Cutter introduces patented automatic center-aligning technology that ensures precise medication division, addressing a critical healthcare need for accurate dosing across personal and professional settings.
ABVC BioPharma Recognized as Promising Biotech Investment Amid Strong Financial Performance and Clinical Progress
ABVC BioPharma's recognition as a top biotech investment opportunity highlights the company's significant financial growth and advancing clinical pipeline across central nervous system disorders and oncology treatments.
NanoViricides' Dual-Track Clinical Strategy for NV-387 Antiviral Drug Highlighted in Analyst Report
NanoViricides is advancing its broad-spectrum antiviral drug candidate NV-387 through a dual-track clinical development strategy targeting both MPox and respiratory viral infections, with potential implications for global pandemic preparedness and biodefense funding opportunities.
Nutriband Partners with Brand Institute to Develop Global Brand Identity for Abuse-Deterrent Fentanyl Patch
Nutriband Inc. has partnered with Brand Institute to create the worldwide commercial brand identity for AVERSA FENTANYL, positioning the product to potentially become the world's first abuse-deterrent opioid patch with significant implications for addressing the opioid crisis.
Lifordi Immunotherapeutics Reports Promising Preclinical Data for Autoimmune Treatment LFD-200
Lifordi Immunotherapeutics will present new preclinical data showing its antibody drug conjugate LFD-200 delivers glucocorticoids directly to immune cells with sustained anti-inflammatory effects and no systemic toxicity, potentially offering a safer treatment option for autoimmune diseases.
Nutriband Files Provisional Patent to Strengthen AVERSA Abuse-Deterrent Technology Protection
Nutriband Inc. has filed a provisional patent application to expand protection for its AVERSA abuse-deterrent transdermal technology, potentially extending patent coverage by 20 years and strengthening the company's position in addressing prescription drug misuse.
Annovis Bio Reports Buntanetap Shows Promising Biomarker Improvements in Alzheimer's Patients
Annovis Bio's buntanetap demonstrated significant reductions in inflammatory biomarkers and improved neuronal health markers in Alzheimer's patients, suggesting potential disease-modifying effects for neurodegenerative conditions.